Therapeutic Potential of iPSC-Derived TH ⁺ /FOXA2 ⁺ Neuronal Extracellular Vesicles in Parkinson’s Disease Revealed by Organoid and Rodent Models
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Parkinson’s disease (PD) is characterized by the progressive loss of midbrain dopaminergic (DA) neurons and aberrant α-synuclein (α-syn) aggregation, yet disease-modifying therapies that simultaneously retard neurodegeneration and foster regeneration remain lacking.
Methods
In this study, we isolated extracellular vesicles (TH⁺/FOXA2⁺ cell-derived EVs) from TH⁺/FOXA2⁺ differentiated neural cells, a distinct midbrain floor-plate-derived neural cell population that co-expresses the floor-plate transcription factor FOXA2 together with TH and should therefore not be equated with conventional mature midbrain dopaminergic neurons, and systematically evaluated their therapeutic potential across three complementary models: A53T transgenic mice, 6-OHDA-lesioned-rats, and 6-OHDA-treated human midbrain organoids. Integrative transcriptomic and single-cell-sequencing analyses, together with toxicological evaluations in rodents and non-human primates, were performed to investigate the underlying mechanisms and safety profile. These TH⁺/FOXA2⁺ cells were generated using a fully suspension-based, matrix-free, and chemically defined differentiation system devoid of N2/B27 supplements and fetal bovine serum (FBS). This approach offers a simple, controllable, low-cost, and scalable platform with high batch-to-batch consistency for EV manufacturing. Throughout this study, the term TH⁺/FOXA2⁺ cells refers to this distinct TH⁺/FOXA2⁺ cell population and should not be interpreted as conventional terminally differentiated dopaminergic neurons.
Results
Intranasal administration of TH⁺/FOXA2⁺ cell-derived EVs in A53T mice and 6-OHDA-lesioned rats significantly ameliorated motor deficits, increased nigral tyrosine hydroxylase (TH)-positive-neuron counts, reduced α-syn-aggregation, and suppressed gliosis. In human midbrain organoids, TH⁺/FOXA2⁺ cell-derived EVs preserved DA neuronal morphology and reduced GFAP and α-syn expression. Notably, when EVs were administered simultaneously with 6-OHDA modeling rather than after modeling was completed, the protective effect was stronger. Multi-omics-analysis revealed that TH⁺/FOXA2⁺ cell-derived EVs reversed pathological signatures of interferon-responsive-microglia and oxidative stress-adapted astrocytes, while restoring WNT and non-canonical-WNT mediated intercellular communications. Safety evaluations showed no discernible organ toxicity.
Conclusions
TH⁺/FOXA2⁺ cell-derived EVs exert neuroprotective effects across multiple PD models by modulating specific glial subpopulations and reinstating development-associated signaling pathways. Together with a fully suspension, matrix-free and N2/B27-free differentiation process that enables low-cost, scalable and highly reproducible manufacturing, TH⁺/FOXA2⁺ cell-derived EVs represent a promising therapeutic candidate for Parkinson’s disease.-